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Purpose of the study
Adherence is a key issue in HIV/AIDS treatment and care
programs. It is important to identify factors that affect
adherence as it relates to survival, development of drug
resistance, disease progression, treatment outcome, and
ability to stay on first-line therapy in resource-poor set-
tings with limited treatment options and expertise for
management.
Methods
384 patients were evaluated with the aid of questionnaires
in 2007, with 320 receiving antiretroviral therapy from
government hospital and 64 from private clinics in Lagos.
Adherence was by self-report of missing pills. The primary
outcome of interest was ≥95% adherence. Logistic regres-
sion was used to model factors affecting adherence.
Summary of results
Mean age: 30.5 years; female: 62%. ≥95% adherence was
associated with partner notification, OR = 0.6 (p < 0.001);
side-effects, OR 1.3 (p = 0.02). 58% were on efavirenz-
containing regimen and 42% on nevirapine. Participants
taking efavirenz were more likely to have ≥95% adherence
than nevirapine-based drugs (40.4% vs. 28.6%, p =
0.017). Multivariate analysis showed that partner notifica-
tion (OR 0.7 [95% CI 0.4–0.8], reduction in number of
pills taken (OR = 0.6 [95% CI 0.3–0.8), and side-effects
(OR 1.7 [95% CI 1.2–2.3] and female (OR 1.2 [95% CI
1.1–1.6] were associated with adherence. 92% preferred
reduction in number of pills taken per day by using com-
bined formulation. 42% attributed stigma as a challenge
to adherence, while 22% reported fear of the drugs, 20%
financial constraint (especially those receiving medication
in private practice), and 18% due to transportation cost to
the treatment facility.
Conclusion
Adherence support, motivation and skills are needed to
sustain our treatment program against virologic and
immunologic failures. Proactive ways of supporting
adherence programs are needed. Additionally, reminder
tools may be needed. It is important to re-enforce partner/
family notification and reduce stigma towards better
adherence. Emphasis should be on the use of combined
HIV drug formulation to reduce daily number of pills
taken.
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